JPWO2011068150A1 - グルカゴン様ペプチド−1分泌促進剤 - Google Patents
グルカゴン様ペプチド−1分泌促進剤 Download PDFInfo
- Publication number
- JPWO2011068150A1 JPWO2011068150A1 JP2011544281A JP2011544281A JPWO2011068150A1 JP WO2011068150 A1 JPWO2011068150 A1 JP WO2011068150A1 JP 2011544281 A JP2011544281 A JP 2011544281A JP 2011544281 A JP2011544281 A JP 2011544281A JP WO2011068150 A1 JPWO2011068150 A1 JP WO2011068150A1
- Authority
- JP
- Japan
- Prior art keywords
- glp
- potato extract
- secretion
- potato
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title claims abstract description 59
- 230000028327 secretion Effects 0.000 title claims abstract description 42
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 title claims abstract description 10
- 102100040918 Pro-glucagon Human genes 0.000 title claims abstract 4
- 244000061456 Solanum tuberosum Species 0.000 claims abstract description 59
- 235000002595 Solanum tuberosum Nutrition 0.000 claims abstract description 59
- 239000000284 extract Substances 0.000 claims abstract description 55
- 235000013305 food Nutrition 0.000 abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 208000008589 Obesity Diseases 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 5
- 235000020824 obesity Nutrition 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 5
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 49
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 24
- 230000001737 promoting effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 238000010828 elution Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100288498 Mus musculus Large1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 241000976924 Inca Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000448053 Toya Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 108010067454 caseinomacropeptide Proteins 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000011899 heat drying method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
GLP−1分泌試験を以下の手順で行った。まず、マウス大腸由来のGLP−1産生細胞株GLUTag(Dr. Daniel J. Drucker, Mount Sinai Hospital Samuel Lunenfeld Research Institute Banting and Best Diabetes Centre, University of Torontoより提供)を、48ウェルプレート中で、10%ウシ胎児血清(FBS)を含むダルベッコ改変イーグル培地にて、37℃、5%CO2存在下、サブコンフルエントになるまで2〜3日間培養した。続いて、ウェルから培養培地を取り除き、Hepesバッファー(140mM NaCl、4.5mM KCl、20mM Hepes、1.2mM CaCl2、1.2mM MgCl2、10mM D-グルコース、0.1% ウシ血清アルブミン(BSA)、pH 7.4)にてウェル中で細胞を洗浄した後、Hepesバッファーに溶解した試験物質溶液80μlを各ウェルに添加し、37℃にて60分間インキュベートした。上清を回収し、800×gで4℃にて5分間、遠心分離して細胞を沈殿させ、その上清70μlを回収し、凍結保存した。凍結保存した上清を適宜解凍し、上清中のGLP−1濃度を、市販のELISAキット(矢内原研究所製)を用いて定量した。上清中のGLP−1濃度(nM)をGLP−1産生細胞株GLUTagからのGLP−1分泌量とした。
ジャガイモ抽出物(株式会社東洋新薬製)(2および10mg/ml);および
ZeinH(トウモロコシ難消化性タンパク質Zeinのパパイン加水分解物:トウモロコシ由来ゼイン(東京化成工業株式会社製)を脱塩水に懸濁してpH7に調整し、パパイン(アサヒビール株式会社製)を基質に対して0.5質量%で添加して55℃にて60分間処理し、煮沸によりパパインを失活させた後、遠心上清を凍結乾燥したもの;2および10mg/ml;陽性コントロールとして使用)。
試験物質として以下を用いたこと以外は、実施例1と同様の試験を行った。
ジャガイモ抽出物(10mg/ml);
ジャガイモ抽出物HP20非吸着画分(7.44mg/ml、ジャガイモ抽出物の10mg/ml分に相当;
ジャガイモ抽出物HP20吸着−20%エタノール溶出画分(1.17mg/ml、ジャガイモ抽出物の10mg/ml分に相当);および
ジャガイモ抽出物HP20吸着−80%エタノール溶出画分(0.45mg/ml、ジャガイモ抽出物の10mg/ml分に相当)。
Claims (1)
- ジャガイモ抽出物を含むグルカゴン様ペプチド−1分泌促進剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011544281A JP5721232B2 (ja) | 2009-12-04 | 2010-12-02 | グルカゴン様ペプチド−1分泌促進剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009276994 | 2009-12-04 | ||
JP2009276994 | 2009-12-04 | ||
JP2011544281A JP5721232B2 (ja) | 2009-12-04 | 2010-12-02 | グルカゴン様ペプチド−1分泌促進剤 |
PCT/JP2010/071555 WO2011068150A1 (ja) | 2009-12-04 | 2010-12-02 | グルカゴン様ペプチド-1分泌促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2011068150A1 true JPWO2011068150A1 (ja) | 2013-04-18 |
JP5721232B2 JP5721232B2 (ja) | 2015-05-20 |
Family
ID=44114996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011544281A Expired - Fee Related JP5721232B2 (ja) | 2009-12-04 | 2010-12-02 | グルカゴン様ペプチド−1分泌促進剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP5721232B2 (ja) |
TW (1) | TW201125573A (ja) |
WO (1) | WO2011068150A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018027982A (ja) * | 2017-11-21 | 2018-02-22 | 株式会社東洋新薬 | 抗糖化用組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6045845B2 (ja) * | 2011-09-02 | 2016-12-14 | 花王株式会社 | Glp−1分泌促進剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010075394A (ko) * | 1999-07-27 | 2001-08-09 | 케민 인더스트리즈, 인코포레이티드 | 식후 포만감을 연장시키기 위한 조성물 |
CN101652147B (zh) * | 2007-04-03 | 2013-07-24 | 田边三菱制药株式会社 | 二肽基肽酶iv抑制化合物和甜味剂的并用 |
-
2010
- 2010-12-02 WO PCT/JP2010/071555 patent/WO2011068150A1/ja active Application Filing
- 2010-12-02 JP JP2011544281A patent/JP5721232B2/ja not_active Expired - Fee Related
- 2010-12-03 TW TW099142029A patent/TW201125573A/zh unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018027982A (ja) * | 2017-11-21 | 2018-02-22 | 株式会社東洋新薬 | 抗糖化用組成物 |
Also Published As
Publication number | Publication date |
---|---|
TW201125573A (en) | 2011-08-01 |
JP5721232B2 (ja) | 2015-05-20 |
WO2011068150A1 (ja) | 2011-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5645360B2 (ja) | ジペプチドを有効成分として含有する組成物 | |
JP5916387B2 (ja) | ジペプチジルペプチダーゼ−4阻害剤 | |
JP6513659B2 (ja) | 糖代謝改善剤 | |
WO2017002786A1 (ja) | Glp-2分泌促進用組成物 | |
AU2018227125A1 (en) | GLP-1 secretagogue and composition | |
JP5721232B2 (ja) | グルカゴン様ペプチド−1分泌促進剤 | |
JP2018516987A (ja) | 阿魏茸の水抽出物を有効成分として含有する代謝性疾患の予防及び治療用薬学的組成物又は健康機能性食品 | |
JPWO2018212362A1 (ja) | α−グルコシダーゼ活性抑制剤 | |
JP5872725B1 (ja) | 鰹節由来のジペプチジルペプチダーゼiv阻害組成物 | |
JP4309108B2 (ja) | 糖尿病治療薬 | |
JP5794678B2 (ja) | グルカゴン様ペプチド−1分泌促進剤 | |
JPWO2006132273A1 (ja) | 摂食抑制作用を有するペプチドを含有する組成物 | |
JP4673071B2 (ja) | 鉄吸着性高分子物質及び鉄含有高分子物質ならびにこれらの製造方法 | |
JP6273440B2 (ja) | Glp−1産生促進剤、dppiv阻害剤及びグルコース吸収阻害剤 | |
JP5674047B2 (ja) | コレシストキニン分泌促進剤 | |
KR101905009B1 (ko) | 면역기능 증진 활성이 있는 케일박 유래 다당 분획물 및 이의 제조방법 | |
TW201639586A (zh) | 紐西蘭鮑(paua)水溶性萃取物 | |
KR101963439B1 (ko) | 아라자임을 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 | |
JP5717433B2 (ja) | 胆汁酸吸着用組成物 | |
JP5297867B2 (ja) | モロヘイヤ抽出物を含有する抗疲労剤又は体力向上剤 | |
JP6636396B2 (ja) | Ampk活性化用組成物 | |
KR20230148629A (ko) | 항비만 및 항당뇨 활성을 갖는 펩타이드 및 이의 용도 | |
JP2024042331A (ja) | そばに由来するタンパク質の加水分解物を含むdppiv阻害剤 | |
JP2019030229A (ja) | 麹菌、麹菌由来の酵素、血糖値上昇抑制剤、飲食品、医薬組成物、食品添加物、サプリメント及びこれらの製造方法、並びに血糖値上昇抑制方法及び糖取り込み促進方法 | |
CN115052612A (zh) | 含有水解乳清蛋白作为活性成分的用于减轻、预防或治疗肌肉减少症的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140717 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140717 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140812 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20140819 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20140909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141010 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141014 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150303 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150320 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5721232 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |